Your browser doesn't support javascript.
loading
SEOM clinical guideline for the management of cutaneous melanoma (2020)
Majem, M; Manzano, J. L; Marquez-Rodas, I; Mujika, K; Muños-Couselo, E; Pérez-Ruiz, E; de la Cruz-Merino, L; Espinosa, E; Gonzalez-Cao, M; Berrocal, A.
Afiliación
  • Majem, M; Hospital de la Santa Creu i Sant Pau. Department of Medical Oncology. Barcelona. Spain
  • Manzano, J. L; ICO-Badalona. Catalan Institute of Oncology. H. Germans Trias i Pujol. Badalona. Spain
  • Marquez-Rodas, I; Instituto de Investigación Sanitaria Gregorio Marañón and CIBERONC. Department of Medical Oncology. Madrid. Spain
  • Mujika, K; OSI Donostialdea-Onkologikoa. UGC de Oncología de Gipuzkoa. Department of Medical Oncology. Guipúzcoa. Spain
  • Muños-Couselo, E; Hospital Vall d’Hebron Barcelona. Vall d’Hebron Institute of Oncology (VHIO). Department of Medical Oncology. Barcelona. Spain
  • Pérez-Ruiz, E; Hospital Universitario Regional Virgen Victoria. Instituto de Investigación Biomédica de Málaga (IBIMA). Hospital Costa del Sol and UGC Oncol. Málaga. Spain
  • de la Cruz-Merino, L; Hospital Universitario Virgen Macarena. Department of Medical Oncology. Seville. Spain
  • Espinosa, E; CIBERONC. Hospital Universitario La Paz. Department of Medical Oncology. Madrid. Spain
  • Gonzalez-Cao, M; Hospital Dexeus. Oncology Department (IOR). Barcelona. Spain
  • Berrocal, A; Consorcio Hospital General Universitario de Valencia. Department of Medical Oncology. Valencia. Spain
Clin. transl. oncol. (Print) ; 23(5): 948-960, mayo 2021. tab, ilus
Article en En | IBECS | ID: ibc-221235
Biblioteca responsable: ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available (AU)
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: IBECS Asunto principal: Neoplasias Cutáneas / Melanoma Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2021 Tipo del documento: Article

Texto completo: 1 Bases de datos: IBECS Asunto principal: Neoplasias Cutáneas / Melanoma Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2021 Tipo del documento: Article